The effects of metoprolol and captopril on heart rate variability in patients with idiopathic dilated cardiomyopathy
- PMID: 10376178
- PMCID: PMC6655613
- DOI: 10.1002/clc.4960220606
The effects of metoprolol and captopril on heart rate variability in patients with idiopathic dilated cardiomyopathy
Abstract
Background: The effects of treatment with captopril or metoprolol on heart rate variability (HRV) were investigated in 38 patients (29 men and 9 women) with mild to moderate symptoms of heart failure due to idiopathic dilated cardiomyopathy (DCM).
Hypothesis: The aim of the study was to investigate and compare the effects of the angiotensin-converting enzyme inhibitor captopril with those of the selective beta-adrenergic receptor blocker metoprolol on HRV in patients with idiopathic DCM.
Methods: Heart rate variability was analyzed in the time and frequency domains from 18th of Holter monitoring before randomized treatment was started, after 6 months of therapy, and 1 month after therapy was stopped.
Results: Captopril treatment increased HRV expressed as total power and low-frequency power in the frequency domain. There was no change in the time domain. In the metoprolol group, there was a pronounced increase in both time- and frequency-domain indices of HRV. The increase in total power was partly maintained 1 month after therapy was stopped in both treatment groups.
Conclusion: Treatment with captopril and metoprolol increases HRV in patients with DCM. This effect seems to be maintained for at least 1 month after therapy is stopped. The increase in HRV seems to be more pronounced with metoprolol, and the two different pharmacologic approaches may have additive effects that are of prognostic importance in patients with heart failure.
Similar articles
-
More favourable haemodynamic effects from metoprolol than from captopril in patients with dilated cardiomyopathy.Eur Heart J. 1997 Jul;18(7):1115-21. doi: 10.1093/oxfordjournals.eurheartj.a015406. Eur Heart J. 1997. PMID: 9243145 Clinical Trial.
-
The circulating renin-angiotensin system during treatment with metoprolol or captopril in patients with heart failure due to non-ischaemic dilated cardiomyopathy.J Intern Med. 1999 May;245(5):435-43. doi: 10.1046/j.1365-2796.1999.00458.x. J Intern Med. 1999. PMID: 10363743
-
Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy.Eur J Heart Fail. 2003 Oct;5(5):679-91. doi: 10.1016/s1388-9842(03)00105-3. Eur J Heart Fail. 2003. PMID: 14607208 Clinical Trial.
-
The role of beta-blockers in the treatment of cardiomyopathy and ischaemic heart failure.Drugs. 1994;47 Suppl 4:31-9; discussion 39-40. doi: 10.2165/00003495-199400474-00006. Drugs. 1994. PMID: 7523060 Review.
-
Controlled trials with beta blockers in heart failure: metoprolol as the prototype.Am J Cardiol. 1993 Mar 25;71(9):45C-53C. doi: 10.1016/0002-9149(93)90086-r. Am J Cardiol. 1993. PMID: 8096675 Review.
Cited by
-
Evaluation of heart rate variability using 24-hour Holter electrocardiography in hypertensive patients.J Arrhythm. 2020 Nov 28;37(1):157-164. doi: 10.1002/joa3.12469. eCollection 2021 Feb. J Arrhythm. 2020. PMID: 33664898 Free PMC article.
-
Comparative Efficacy of Different Drugs for the Treatment of Dilated Cardiomyopathy: A Systematic Review and Network Meta-analysis.Drugs R D. 2023 Sep;23(3):197-210. doi: 10.1007/s40268-023-00435-5. Epub 2023 Aug 9. Drugs R D. 2023. PMID: 37556093 Free PMC article.
-
Ivabradine improves heart rate variability in patients with nonischemic dilated cardiomyopathy.Arq Bras Cardiol. 2014 Oct;103(4):308-14. doi: 10.5935/abc.20140109. Epub 2014 Aug 13. Arq Bras Cardiol. 2014. PMID: 25119894 Free PMC article.
-
Secondary outcomes of a behavioral sleep intervention: A randomized clinical trial.Health Psychol. 2019 Mar;38(3):196-205. doi: 10.1037/hea0000700. Health Psychol. 2019. PMID: 30762399 Free PMC article. Clinical Trial.
-
Heart rate variability and cardiovascular mortality.Curr Atheroscler Rep. 2002 Mar;4(2):120-7. doi: 10.1007/s11883-002-0035-1. Curr Atheroscler Rep. 2002. PMID: 11822975 Review.
References
-
- Pomeranz B, Macaulay RJ, Caudill MA, Kutz I, Adam D, Gordon D, Kilborn KM, Barger AC, Shannon DC, Cohen RJ: Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol 1985; 248: H151–153 - PubMed
-
- Kjellgren O, Gomes J: Heart rate variability and baroreflex sensitivity in myocardial infarction. Am Heart J 1993; 125: 204–215 - PubMed
-
- Kleiger R, Miller J, Bigger J, Moss A: Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59: 256–262 - PubMed
-
- Pipilis A, Flather M, Ormerod O, Sleight P: Heart rate variability in acute myocardial infarction and its association with infarct size and clinical course. Am J Cardiol 1991; 67: 1137–1139 - PubMed
-
- Farrell TG, Bashir Y, Cripps T, Malik M, Poliniecki J, Bennet ED, Bennett ED, Ward DE, Camm AJ: Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal‐average electrocardiogram. J Am Coll Cardiol 1991; 18: 687–697 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources